Navigation Links
Silence Therapeutics Receives Comprehensive Protection for RNAi Structural Modification Technology in Single European Patent
Date:10/20/2010

LONDON, Oct. 20 /PRNewswire/ -- Silence Therapeutics plc (AIM: SLN) ("Silence" or the "Company") announces that the European Patent Office (EPO) has granted a new patent that provides broad protection on novel aspects of the RNAi structural modification technology known as the "Zamore Design Rules."  European patent number 1 633 890 titled "Methods and Compositions for Enhancing the Efficacy and Specificity of RNAi" was published today in the European Patent Bulletin.  The European patent covers various breakthrough structural modification methods and compositions which Silence believes are fundamental for the development and commercialization of RNAi therapeutics with enhanced efficacy.

"The granting of this comprehensive patent in Europe is a significant milestone for Silence in our ongoing effort to build one of the world's leading RNAi intellectual property positions.  We have consistently built a strong IP estate around the Zamore technology in the U.S. and have now extended our global coverage to Europe with the granting of this critical patent," stated Philip Haworth, Ph.D., chief executive officer of Silence Therapeutics.  "We have often stated our belief that the 'Zamore Design Rules' represent significant IP to enable the process of bringing effective RNAi therapeutics to market.  With this latest patent grant from the EPO, we are excited to be able to offer potential collaborators or licensing partners access to this strongly protected Zamore technology in both the U.S. and Europe."

The issued patent's method and composition claims include:

  • Methods of enhancing the ability of an antisense strand of an RNAi agent to act as a guide strand
  • RNAi or siRNA agents for enhancing silencing of a target mRNA in a subject
  • Compositions for siRNA duplexes include pre-miRNA and shRNA and vectors to perform the methods described herein

Silence owns excl
'/>"/>

SOURCE Silence Therapeutics plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
2. Silence Therapeutics Expands RNAi Structural Modification IP Portfolio With Issuance of New U.S. Patent
3. Silence Therapeutics Issued Novel RNAi Patent Covering High-Value Cancer Target in United States
4. Silence Therapeutics Appoints New Vice President of Research
5. Silence Therapeutics to Present at 12th Annual BIO CEO & Investor Conference
6. National Ovarian Cancer Coalition and PureOlogy to Host First Annual NOCC and PureOlogys Walk to Break the Silence on Ovarian Cancer
7. Precision Therapeutics President and CEO Sean McDonald Recognized as Pittsburgh Technology Council Tech 50 CEO of the Year
8. Fate Therapeutics Announces Collaboration With BD to Develop and Commercialize Induced Pluripotent Stem Cell Technology
9. Northwest Biotherapeutics to Present at Inaugural Cancer Immunotherapy Conference
10. Orexigen® Therapeutics Announces Upcoming Data Presentations at the 28th Annual Scientific Meeting of The Obesity Society
11. Cell Therapeutics, Inc. (CTI) to Present at 9th Annual BIO Investor Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... IDAHO (PRWEB) March 05, 2015 ... Ultralight Histology’s paraffin and stain additive. The improvement ... observe the binary features present in all daughter ... FFPE protocol, chromatin packaging was analyzed at 1000-1600x ... indicated that chromatin patterning in all daughter cells ...
(Date:3/5/2015)... Research and Markets ( http://www.researchandmarkets.com/research/4ld5nw/mature_biotech ) ... Outlook 2015: New Therapy Ventures Pave the Way for ... All biotech companies - Gilead (GILD), Amgen (AMGN), Biogen ... given a positive return and hence increased the interest ... select therapy/niche indication where the high treatment cost justifies ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 ... acute and chronic orthopedic conditions such as meniscal ... tennis elbow, and joint pain due to degenerative ... administered during orthopedic surgeries to promote better post-surgical ... advances in nearly pain-free bone marrow harvesting with ...
(Date:3/4/2015)... March 4, 2015  Brooklyn residents now have a ... chronic pain and injuries. Nunzio Saulle , M.D., ... opening of his NJS Physical Medicine and Rehabilitation (PM&R) ... Thursday, March 5, 2015. Health Plus Management, LLC is ... located at 1178 Flatbush Avenue. This new PM&R practice ...
Breaking Biology Technology:Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success 2Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success 3Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 2Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 3Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 4Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas on Friday, March 6th from 5:30 pm to 7:30 pm. 5NJS Physical Medicine & Rehabilitation Opening on Flatbush Avenue, Brooklyn, NY 2
... State University of Pennsylvania (USA) and the Universidad Autnoma ... biological structures, such as butterfly wings, on a nano ... optically active structures, such as optical diffusers for solar ... to change colours depending on the angle) or their ...
... Germany, October 9 Pieris AG, the,biopharmaceutical company ... protein therapeutics, today reported continued progress in development,of ... Under its manufacturing agreement ... biopharmaceuticals, Pieris has,successfully completed the first cGMP run ...
... Oct. 9 Soligenix, Inc. (Soligenix or the Company), ... today that Robert J. Rubin, MD, has been appointed ... had a distinguished career in the healthcare industry and ... president of the national health policy and management consulting ...
Cached Biology Technology:Nanometric butterfly wings created 2Pieris Reports Preclinical Development Progress of its Next Generation VEGF Antagonist 2Pieris Reports Preclinical Development Progress of its Next Generation VEGF Antagonist 3Soligenix Appoints Robert J. Rubin, MD, to its Board of Directors 2Soligenix Appoints Robert J. Rubin, MD, to its Board of Directors 3Soligenix Appoints Robert J. Rubin, MD, to its Board of Directors 4
(Date:1/22/2015)... , Jan. 22, 2015 Research and Markets ( ... - A Global Market Overview" report to their offering. ... is to ensure that an individual is who she/he is ... make use of a person,s unique physical characteristics, such as ...
(Date:1/22/2015)... , Jan. 13, 2015  Today, FreeWavz ( ... launched its crowdfunding campaign on Fundable, https://www.fundable.com/freewavz ... build of production capacity to meet customer demand. ... Photo - http://photos.prnewswire.com/prnh/20150113/168790 ...
(Date:1/22/2015)... man-made form of insulin delivered by nasal spray may ... with mild cognitive impairment and Alzheimer,s disease dementia, according ... Forest Baptist Medical Center. The study,s subjects ... (MCI) or mild to moderate Alzheimer,s dementia (AD). Those ...
Breaking Biology News(10 mins):Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3
... Depressed individuals with a tendency to ruminate on ... thoughts or memories, show different patterns of brain network ... new study in Biological Psychiatry . The ... tendency towards negative ruminations, but patterns of autobiographic memory ...
... in German . , Neutrophil granulocytes comprise ... the body, they are the first on the scene to ... risk. To this end, they release serine proteases enzymes ... at the Max Planck Institute of Neurobiology in Martinsried have ...
... a smoking gun proving that increased fertilizer use over the ... atmospheric nitrous oxide, which is a major greenhouse gas contributing ... the cause of the increased nitrous oxide was nitrogen-based fertilizer, ... nitrous oxide at a faster rate than normal. ...
Cached Biology News:Activity in brain networks related to features of depression 2New immune defense enzyme discovered 2New immune defense enzyme discovered 3Fertilizer use responsible for increase in nitrous oxide in atmosphere 2Fertilizer use responsible for increase in nitrous oxide in atmosphere 3Fertilizer use responsible for increase in nitrous oxide in atmosphere 4
... Signet offers the most comprehensive, ... requirements. We have incorporated unprecedented quality ... capabilities. This includes proven detection chemistries ... to the TechMate protocol. It also ...
Functionally tested for consistent G-banding of chromosomes....
... Cell Medium is optimized for serum-free growth ... In this protein-free medium, Sf9 cultures routinely ... cells/ml with viabilities above 95%. This medium ... color from X-gluc staining of pBACgus recombinants ...
... Insect Medium is formuatled for the ... Sf9 and Sf21 cells. Grace's Insect ... because it does not contain lactalbumin ... with transfection. Grace's Insect Medium, Supplemented ...
Biology Products: